학술논문
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
Document Type
Article
Author
Brown-Burke, Fiona; Hwang, Inah; Sloan, Shelby; Hinterschied, Claire; Helmig-Mason, JoBeth; Long, Mackenzie; Chan, Wing Keung; Prouty, Alexander; Chung, Ji-Hyun; Zhang, Yang; Singh, Satishkumar; Youssef, Youssef; Bhagwat, Neha; Chen, Zhengming; Chen-Kiang, Selina; Di Liberto, Maurizio; Elemento, Olivier; Sehgal, Lalit; Alinari, Lapo; Vaddi, Kris; Scherle, Peggy; Lapalombella, Rosa; Paik, Jihye; Baiocchi, Robert A.
Source
Blood Advances; October 2023, Vol. 7 Issue: 20 p6211-6224, 14p
Subject
Language
ISSN
24739529; 24739537
Abstract
•PRMT5 inhibition induces a FOXO1 driven, proapoptotic program in MCL.•Combination therapy with PRMT5 and BCL-2 inhibition is synergistic in preclinical MCL models, including those with ibrutinib resistance.